300841 康华生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.9486.29611.45315.45520.817
总资产报酬率 ROA (%)3.5375.4729.68012.85817.776
投入资产回报率 ROIC (%)3.8445.98610.83214.66520.247

边际利润分析
销售毛利率 (%)89.76592.03594.20393.45393.562
营业利润率 (%)29.53822.30632.63436.55547.383
息税前利润/营业总收入 (%)29.22421.90932.01935.88546.507
净利润/营业总收入 (%)26.21918.87527.84132.28241.339

收益指标分析
经营活动净收益/利润总额(%)103.661103.895119.201107.69097.339
价值变动净收益/利润总额(%)4.4550.716-12.598-5.4448.322
营业外收支净额/利润总额(%)-0.086-0.049-0.056-0.456-0.250

偿债能力分析
流动比率 (X)7.6505.7434.3933.8973.507
速动比率 (X)7.2475.4234.0813.6433.256
资产负债率 (%)8.98711.77914.40316.51617.122
带息债务/全部投入资本 (%)-0.1733.5735.0135.0864.473
股东权益/带息债务 (%)-57,253.0902,674.0321,887.3911,859.1922,130.120
股东权益/负债合计 (%)1,012.731748.965594.323505.461484.054
利息保障倍数 (X)-101.195-56.689-53.596-71.230-61.344

营运能力分析
应收账款周转天数 (天)421.070390.035340.596307.828264.297
存货周转天数 (天)442.483616.223759.877570.290500.834